Cue Biopharma Announces Approximately $20 Million Public Offering
April 18, 2025
April 18, 2025
WASHINGTON, April 18 -- WilmerHale, a law firm, issued the following news:
* * *
Cue Biopharma Announces Approximately $20 Million Public Offering
On April 14, 2025, Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced the pricing of an underwritten public offering of shares of its c . . .
* * *
Cue Biopharma Announces Approximately $20 Million Public Offering
On April 14, 2025, Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced the pricing of an underwritten public offering of shares of its c . . .